Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB

Authors

Nelson, Peter T., Kryscio, Richard J., Abner, Erin L., Schmitt, Frederick A., Jicha, Gregory A., Mendiondo, Marta S., Cooper, Greg, Smith, Charles B., Markesbery, William R.

Journal

Journal of Alzheimer's Disease, Volume: 16, No.: 1, Pages.: 29-34

Year of Publication

2009

Abstract

Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = 5) or patients that were profoundly demented at recruitment (intake MMSE < 20; n = 86) were excluded to strengthen our ability to test the association of specific clinical and pathological indices. Patients with pathologically-diagnosed AD + DLB (n = 25) lost cognitive capacity faster than patients with AD alone (n = 40). In both diseases, treatment with acetylcholinesterase inhibitors was associated with a slower rate of cognitive decline. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)

Keywords

acetylcholinesterase, acetylcholinesterase inhibitor treatment, alzheimer’s disease, cognitive impairment, dementia with lewy bodies, drug therapy, enzyme inhibitors, inhibitors, patients, slow cognitive decline

Countries of Study

USA

Types of Dementia

Alzheimer’s Disease, Lewy-Body

Types of Study

Cohort Study

Type of Outcomes

Cognition

Type of Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime